Recombinant Trimeric S Subunit Vaccine

Specification

• Cat#: HIV-291
• Product Name: Recombinant Trimeric S Subunit Vaccine
• Description: SCB-2019 is a recombinant trimeric S protein subunit vaccine candidate being investigated against COVID-19. This vaccine candidate resembles the native trimeric viral spike and is produced through mammalian cell-culture. The vaccine was developed and tested by Clover Biopharmaceuticals AUS Pty Ltd.. As of June 2020, the company is pursuing a randomized, double blind, placebo controlled study (NCT04405908) to test the safety and immunogenicity of the vaccine.

Pharmaceutical Information

• Pharmaceutical Application: SCB-2019